Stock ARWR ARROWHEAD PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Market Closed - Nasdaq
Other stock markets
 01:00:00 2024-07-03 pm EDT 		5-day change 1st Jan Change
25.07 USD -0.59% Intraday chart for Arrowhead Pharmaceuticals, Inc. -2.41% -18.07%
Jun. 25 Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study MT
Jun. 25 Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Arrowhead Pharmaceuticals to Advance Investigational Medicine Plozasiran Into Late-stage Cardiovascular Study
MT
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
BU
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial
CI
Sector Update: Health Care Stocks Advance Monday Afternoon
MT
Arrowhead Says Potential Obesity Treatment Shows 'Promising' Preclinical Results -- Shares Rise
MT
Arrowhead Pharmaceuticals : American Diabetes Association (ADA) 84th Scientific Sessions View Presentation
PU
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
BU
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Arrowhead Pharmaceuticals' Plozasiran Lowers Triglycerides in Phase 3 Trial; Shares Rise
MT
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
BU
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome
CI
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
BU
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
BU
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
BU
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
CI
Transcript : Arrowhead Pharmaceuticals, Inc. - Special Call
Arrowhead Pharmaceuticals Lung Disease Treatment Study Shows Lower Serum sRAGE in Asthma Patients
MT
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
BU
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ARWR Stock
  4. News Arrowhead Pharmaceuticals, Inc.